title: Urinary gonadotropin fragment, a new tumor marker. IV. Use in endometrial cancers and uterine mixed mullerian tumors.
abstract: The use of urinary gonadotropin fragment (UGF) and CA-125 measurements was examined in the diagnosis and management of endometrial cancers and uterine mixed mullerian tumors. Using a cutoff of 3 fmole/ml for UGF, 37 of 63 (59%) patients with active cancer and 4 of 78 (5%) women with no evidence of disease after successful treatment had elevated levels of UGF. Similar results were obtained for CA-125 (cutoff greater than or equal to 35 U/ml) in the same patients, with elevated levels in 54% of patients with active disease and in 4% of patients with no evidence of disease. Sensitivities and mean values of UGF and CA-125 increased significantly with advancing stage and histologic grade of differentiation. Compared to patients with intrauterine disease only, patients with extra-uterine disease had a significant positivity rate and increased mean values for each tumor marker. The presence of lymph node metastases and levels of UGF showed a significant correlation; there was a significant relationship between CA-125 levels and positive cytology of peritoneal washing. Levels of UGF and CA-125 reflected the clinical courses of disease during therapy. During this study period, 85% of tumor recurrences could be anticipated before the clinical manifestation by elevated UGF and CA-125 levels. All patients who died of advanced or recurrent cancers had elevated levels of UGF and CA-125 before death and the mean values of both markers in these patients were significantly higher than those of both markers in the alive group.
authors.affiliation: Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, Connecticut 06510.
authors.forename: J H
authors.initials: JH
authors.lastname: Nam
authors.forename: J T
authors.initials: JT
authors.lastname: Chambers
authors.forename: P E
authors.initials: PE
authors.lastname: Schwartz
authors.forename: L A
authors.initials: LA
authors.lastname: Cole
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000378:metabolism; D002291:Carcinoma, Papillary / Q000378:metabolism; D006063:Chorionic Gonadotropin / Q000378:metabolism*; D018997:Chorionic Gonadotropin, beta Subunit, Human; D005260:Female; D006801:Humans; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D009373:Neoplasms, Germ Cell and Embryonal / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D010446:Peptide Fragments / Q000378:metabolism*; D011379:Prognosis; D014594:Uterine Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D006063:Chorionic Gonadotropin; D018997:Chorionic Gonadotropin, beta Subunit, Human; D010446:Peptide Fragments; C063554:urinary gonadotropin fragment